Contact this trialFirst, we need to learn more about you.
Sodium-glucose cotransporter 2 (SGLT2) inhibitor
Empagliflozin for Kidney Disease
Recruiting2 awardsPhase 4
New Haven, Connecticut
This trial is testing if empagliflozin can help patients with severe kidney disease on dialysis by reducing their sugar absorption. The medication works by helping the kidneys remove sugar from the blood. Empagliflozin has been shown to improve kidney outcomes and slow the progression of diabetic kidney disease in previous trials.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service